MedTrace Logo

A Pharmacodynamic Study With Ticagrelor in African American Patients

NCT01523392 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.

Conditions

  • Stable Coronary Artery Disease

Interventions

DRUG

Ticagrelor

Min - 90mg/Max - 180mg tablets (loading dose)

DRUG

Clopidogrel

75mg (once daily)/Max - 600mg tablets (loading dose)

Sponsors & Collaborators

Principal Investigators

  • Glenn Carlson, MD · AstraZeneca Pharmaceuticals Room C3B-718PO Box 15437 Wilmington, DE 19850-5437 USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01523392 on ClinicalTrials.gov